Clinical Benefits of Piperacillin/Tazobactam versus a Combination of Ceftriaxone and Clindamycin in the Treatment of Early, Non-Ventilator, Hospital-Acquired Pneumonia in a Community-Based Hospital
Ga Eun Park,1 Jae-Hoon Ko,2 Hyun Kyun Ki1 1Division of Infectious Disease, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Korea; 2Division of Infectious Diseases, Department of Internal Medicine, Samsung Medical Center, Seoul, KoreaCorrespondence: Hyun Kyun KiDivision...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2020-09-01
|
| Series: | International Journal of General Medicine |
| Subjects: | |
| Online Access: | https://www.dovepress.com/clinical-benefits-of-piperacillintazobactam-versus-a-combination-of-ce-peer-reviewed-article-IJGM |
| _version_ | 1828810565992054784 |
|---|---|
| author | Park GE Ko JH Ki HK |
| author_facet | Park GE Ko JH Ki HK |
| author_sort | Park GE |
| collection | DOAJ |
| description | Ga Eun Park,1 Jae-Hoon Ko,2 Hyun Kyun Ki1 1Division of Infectious Disease, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Korea; 2Division of Infectious Diseases, Department of Internal Medicine, Samsung Medical Center, Seoul, KoreaCorrespondence: Hyun Kyun KiDivision of Infectious Diseases, Konkuk University Medical Center, Konkuk University School of Medicine, 120-1, Neungdong-Ro, Gwangjin-gu, Seoul 05030, Republic of KoreaTel +82-2-2030-7546Email kihkdr@kuh.ac.krPurpose: There is an increasing prevalence of multidrug-resistant (MDR) organisms worldwide. Therefore, broad-spectrum antibiotics are recommended in the treatment of hospital-acquired pneumonia (HAP). However, it remains controversial whether patients with early onset, non-ventilator HAP (NV-HAP) should also be empirically treated with broad-spectrum antibiotics. We compared the clinical benefit of ceftriaxone plus clindamycin vs piperacillin/tazobactam as the initial empirical treatment of adults with early NV-HAP.Patients and Methods: Retrospective cohort study was conducted in adult patients who were diagnosed with early, NV-HAP between January 2013 and June 2017 at a community-based tertiary care hospital. Patients were eligible for inclusion if they had received empiric treatment with either ceftriaxone and clindamycin or piperacillin/tazobactam for at least 3 days. Patients with increased risk of MDR pathogens were excluded.Results: A total of 89 patients were treated with ceftriaxone and clindamycin, while 124 received piperacillin/tazobactam. There were no significant differences between the two antibiotic groups with regard to median age, sex, or risk of pneumonia. The 30-day all-cause mortality did not differ significantly between the ceftriaxone plus clindamycin and piperacillin/tazobactam groups (4.5% vs 1.6%, P=0.202, respectively). However, in multivariate analysis, clinical failure was more frequent in the ceftriaxone plus clindamycin group than in the piperacillin/tazobactam group (HR 3.316; 95% CI, 1.589– 6918, P=0.001).Conclusion: Treatment with piperacillin/tazobactam was more effective than that with ceftriaxone plus clindamycin in patients with early NV-HAP. This study supports the recent treatment recommendations that patients with early NV-HAP should be treated empirically with broad-spectrum antibiotics.Keywords: empirical antibiotics, hospital-acquired infection, pneumonia, multiple drug resistance |
| first_indexed | 2024-12-12T09:13:43Z |
| format | Article |
| id | doaj.art-c68e02cfeccc4148a3061caa28b37fbd |
| institution | Directory Open Access Journal |
| issn | 1178-7074 |
| language | English |
| last_indexed | 2024-12-12T09:13:43Z |
| publishDate | 2020-09-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | International Journal of General Medicine |
| spelling | doaj.art-c68e02cfeccc4148a3061caa28b37fbd2022-12-22T00:29:27ZengDove Medical PressInternational Journal of General Medicine1178-70742020-09-01Volume 1370571257340Clinical Benefits of Piperacillin/Tazobactam versus a Combination of Ceftriaxone and Clindamycin in the Treatment of Early, Non-Ventilator, Hospital-Acquired Pneumonia in a Community-Based HospitalPark GEKo JHKi HKGa Eun Park,1 Jae-Hoon Ko,2 Hyun Kyun Ki1 1Division of Infectious Disease, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Korea; 2Division of Infectious Diseases, Department of Internal Medicine, Samsung Medical Center, Seoul, KoreaCorrespondence: Hyun Kyun KiDivision of Infectious Diseases, Konkuk University Medical Center, Konkuk University School of Medicine, 120-1, Neungdong-Ro, Gwangjin-gu, Seoul 05030, Republic of KoreaTel +82-2-2030-7546Email kihkdr@kuh.ac.krPurpose: There is an increasing prevalence of multidrug-resistant (MDR) organisms worldwide. Therefore, broad-spectrum antibiotics are recommended in the treatment of hospital-acquired pneumonia (HAP). However, it remains controversial whether patients with early onset, non-ventilator HAP (NV-HAP) should also be empirically treated with broad-spectrum antibiotics. We compared the clinical benefit of ceftriaxone plus clindamycin vs piperacillin/tazobactam as the initial empirical treatment of adults with early NV-HAP.Patients and Methods: Retrospective cohort study was conducted in adult patients who were diagnosed with early, NV-HAP between January 2013 and June 2017 at a community-based tertiary care hospital. Patients were eligible for inclusion if they had received empiric treatment with either ceftriaxone and clindamycin or piperacillin/tazobactam for at least 3 days. Patients with increased risk of MDR pathogens were excluded.Results: A total of 89 patients were treated with ceftriaxone and clindamycin, while 124 received piperacillin/tazobactam. There were no significant differences between the two antibiotic groups with regard to median age, sex, or risk of pneumonia. The 30-day all-cause mortality did not differ significantly between the ceftriaxone plus clindamycin and piperacillin/tazobactam groups (4.5% vs 1.6%, P=0.202, respectively). However, in multivariate analysis, clinical failure was more frequent in the ceftriaxone plus clindamycin group than in the piperacillin/tazobactam group (HR 3.316; 95% CI, 1.589– 6918, P=0.001).Conclusion: Treatment with piperacillin/tazobactam was more effective than that with ceftriaxone plus clindamycin in patients with early NV-HAP. This study supports the recent treatment recommendations that patients with early NV-HAP should be treated empirically with broad-spectrum antibiotics.Keywords: empirical antibiotics, hospital-acquired infection, pneumonia, multiple drug resistancehttps://www.dovepress.com/clinical-benefits-of-piperacillintazobactam-versus-a-combination-of-ce-peer-reviewed-article-IJGMempirical antibioticshospital acquired infectionpneumoniamultiple drug resistance |
| spellingShingle | Park GE Ko JH Ki HK Clinical Benefits of Piperacillin/Tazobactam versus a Combination of Ceftriaxone and Clindamycin in the Treatment of Early, Non-Ventilator, Hospital-Acquired Pneumonia in a Community-Based Hospital International Journal of General Medicine empirical antibiotics hospital acquired infection pneumonia multiple drug resistance |
| title | Clinical Benefits of Piperacillin/Tazobactam versus a Combination of Ceftriaxone and Clindamycin in the Treatment of Early, Non-Ventilator, Hospital-Acquired Pneumonia in a Community-Based Hospital |
| title_full | Clinical Benefits of Piperacillin/Tazobactam versus a Combination of Ceftriaxone and Clindamycin in the Treatment of Early, Non-Ventilator, Hospital-Acquired Pneumonia in a Community-Based Hospital |
| title_fullStr | Clinical Benefits of Piperacillin/Tazobactam versus a Combination of Ceftriaxone and Clindamycin in the Treatment of Early, Non-Ventilator, Hospital-Acquired Pneumonia in a Community-Based Hospital |
| title_full_unstemmed | Clinical Benefits of Piperacillin/Tazobactam versus a Combination of Ceftriaxone and Clindamycin in the Treatment of Early, Non-Ventilator, Hospital-Acquired Pneumonia in a Community-Based Hospital |
| title_short | Clinical Benefits of Piperacillin/Tazobactam versus a Combination of Ceftriaxone and Clindamycin in the Treatment of Early, Non-Ventilator, Hospital-Acquired Pneumonia in a Community-Based Hospital |
| title_sort | clinical benefits of piperacillin tazobactam versus a combination of ceftriaxone and clindamycin in the treatment of early non ventilator hospital acquired pneumonia in a community based hospital |
| topic | empirical antibiotics hospital acquired infection pneumonia multiple drug resistance |
| url | https://www.dovepress.com/clinical-benefits-of-piperacillintazobactam-versus-a-combination-of-ce-peer-reviewed-article-IJGM |
| work_keys_str_mv | AT parkge clinicalbenefitsofpiperacillintazobactamversusacombinationofceftriaxoneandclindamycininthetreatmentofearlynonventilatorhospitalacquiredpneumoniainacommunitybasedhospital AT kojh clinicalbenefitsofpiperacillintazobactamversusacombinationofceftriaxoneandclindamycininthetreatmentofearlynonventilatorhospitalacquiredpneumoniainacommunitybasedhospital AT kihk clinicalbenefitsofpiperacillintazobactamversusacombinationofceftriaxoneandclindamycininthetreatmentofearlynonventilatorhospitalacquiredpneumoniainacommunitybasedhospital |